A Novel Antiapoptosis Inhibitor, Survivin is Expressed in Uterine Cervical Cancer: The Relationship with prognostic Factors.

Objective: A novel inhibitor of apoptosis, survivin, seems to be involved in critical steps of cancer onset and progression, and associated with unfavorable clinical outcome. We investigated the expression of survivin in patients with cervical intraepithelial neoplasm and uterine cervical cancer to determine whether survivin indicates the poor prognosis or not. Methods: The study included 14 cases of cervical intraepithelial neoplasia grade III, 53 cases of invasive uterine cervical squamous cell carcinoma. Immunohistochemical stain and western blot was performed with antihuman survivin antibody. Results: Survivin was highly expressed in CIN III and cervical cancer group than normal control group (p4 cm, lymphovascular invasion, elevated SCC Ag. level, and nonresponse to initial therapy. As the clinical stage goes up, survivin expression had a tendency to increase but there was no statistical significance (p=0.081). No association was noted between survivin expression and survival rate (p=0.1011). Conclusion: This results suggest that survivin expression may provide prognostic information and could represent a possible new marker of prognosis in uterine cervical squamous cell carcinoma patients.